我們已在上線! 進一步了解
CALA

Calithera Biosciences, Inc

已下市

CALA已於2023年2月1日下市。

 

關於: Calithera Biosciences Inc is a clinical-stage pharmaceutical company. The business activity of the firm functions through the region of the US. It focuses on discovering and developing small molecule drugs directed against tumor and immune cell targets that control key metabolic pathways in the tumor microenvironment. Its lead product candidate is CB-839, an inhibitor of glutaminase for the treatment of solid tumors. Its other product candidate, CB-1158, is being developed for hematology and oncology indications.

員工: 63

新聞

正面
中性
負面
市場情緒 3個月
正面 0%
中性 0%
負面 0%

我們尚未收到任何關於CALA的最新新聞文章。

價格圖表採用Lightweight Charts™實作